LG-13. SECOND-LINE TREATMENT FOR PEDIATRIC LOW GRADE GLIOMA (LGG) EXPERIENCES FROM THE GERMAN AND SWISS SIOP-LGG-2004 COHORT Daniela Kandels1, Rene Schmidt2, Sabine Breitmoser-Greiner1, and Astrid K. Gnekow1; Children’s Hospital, Klinikum Augsburg, 86156 Augsburg, Germany; Institute of Biostatistics and Clinical Research, University of Muenster, 48149 Muenster, Germany OBJECTIVE: Though chemo(CT) and radiotherapy (RT) are effective for non-resectable pediatric LGG, progression following first non-surgical treatment is frequent. Wereport results for salvage-therapy of events after first nonsurgical treatment.METHODSAND RESULTS: 180 events followed primary treatment in the SIOP-LGG-2004-trial (30/169 RT [2/10 NF1]; 150/321 CT [37/124 NF1]), median follow-up (FU) since start of first therapy: 6.9 years. 54/150 events occurred during chemotherapy (early, 18/54 died), 96/150 after termination (median time to progression: 3.0 years, 5/96 died). Second-line-radiotherapy: 3/30 RT-, 43/150 CT-patients. Second-line-chemotherapy: 14/30 RT-, 70/150 CT-patients. Followingmultiple progressions 3 or more lines of rescue-therapy were applied in 7/30 RT-, 46/150 CT-patients. Vincristin/cisplatin/cyclophosphamide (VCR/Cis/Cyc, n 1⁄4 25), vincristin/carboplatin (VCR/Carb, n 1⁄4 25), vinblastine (VBL, n 1⁄4 19) and temozolomide (TMZ, n 1⁄4 8) were used most commonly as second-line chemotherapy. Median time to next progression varied between drugs: VCR/Carb 2.4 years (median FU 3.5 years), VCR/Cis/Cyc 1.9 years (median FU 6.6 years), VBL 1.1 years (median FU 1.5 years), TMZ 0.9 years (median FU 4.4 years). 30/180 patients died. Three-years-overall-survival since first event after start of first therapy differed for patients with vs. without dissemination (75.0% vs. 88.2%, p 1⁄4 0.043), diffuse glioma WHO-grade II vs. other histologies (61.5% vs. 86.6%, p 1⁄4 0.018), with a trend for caudal-brainstem-site vs. other localization (73.8% vs. 86.8%, p 1⁄4 0.105). CONCLUSION: Although progression of non-resectable LGG is frequent following first-line therapy, patients can be salvaged by subsequent treatment(s). Second progression-free survival is longer following platinumbased chemotherapy. Impaired survival after first treatment-failure seems to be associated with dissemination, diffuse histology, caudal-brainstem-site and early events. Standardized second-line treatment-protocols are required. Neuro-Oncology 18:iii78–iii96, 2016. doi:10.1093/neuonc/now075.13 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Read full abstract